University of Connecticut Department of Nutritional Sciences
Welcome,         Profile    Billing    Logout  
 8 Trials 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chun, Ock
NCT06227247: Meals 4 Moms: A Multilevel Community-based Lifestyle Intervention for GDM

Recruiting
N/A
40
US
Meals4Moms Intervention
UConn Health, University of Connecticut, Trinity Health Of New England, Hartford Hospital
Gestational Diabetes
09/24
09/24
Adams, Mark
CHALLENGE-MIG, NCT05127486: A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

Checkmark Enrollment initiated in combination with Emgality for episodic migraine
Nov 2021 - Nov 2021: Enrollment initiated in combination with Emgality for episodic migraine
Completed
4
580
US
Galcanezumab, LY2951742, Rimegepant, Placebo
Eli Lilly and Company
Migraine, Episodic Migraine
05/23
05/23
NCT05590403 / 2022-001981-36: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

Completed
3
1544
Europe, Canada, Japan, US, RoW
RSVPreF3 OA investigational vaccine, Placebo
GlaxoSmithKline
Respiratory Syncytial Virus Infections
03/23
04/24
NCT05264506: Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

Terminated
3
2007
US
NOMAC-E2 COC, Nomegestrol acetate / estradiol
Organon and Co, IQVIA Inc., OSTAtistics
Contraception
01/24
01/24
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06389487: A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

Active, not recruiting
3
1457
Europe, Canada, Japan, US, RoW
RSVPreF3 OA investigational vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
07/24
04/25
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
ORCA-OL, NCT06435221: Safety Study of Cytisinicline in Adult Combustible And/or E-cigarette Smokers

Active, not recruiting
3
650
US
Cytisinicline, Cytisine
Achieve Life Sciences
Smoking Cessation, Vaping Cessation
12/25
12/25
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting
3
12000
Europe, Canada, Japan, US, RoW
RSVPreF3 OA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
09/26
09/26
ANCHOR-1, NCT05274750 / 2021-005037-16: Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in US for CRSwNP
Completed
3
276
Europe, Canada, Japan, US, RoW
Depemokimab (GSK3511294), Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nasal Polyps
07/24
08/24
NCT06007183: Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Recruiting
3
800
US
CHIKV VLP vaccine booster, PXVX0317, Placebo booster
Bavarian Nordic
Chikungunya Virus Infection
04/28
08/28
NCT06431607: A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

Active, not recruiting
2
838
US
Flu Seasonal mRNA Formulation 1, GSK4382276A, Flu Seasonal mRNA Formulation 2, Flu Seasonal mRNA Formulation 3, Flu Seasonal mRNA Formulation 4, Flu Seasonal mRNA Formulation 5, Flu Seasonal mRNA Formulation 6, Flu Seasonal mRNA Formulation 7, Flu Seasonal mRNA Formulation 8, Active Comparator 1, Active Comparator 2, Flu Seasonal mRNA Formulation 9, Flu Seasonal mRNA Formulation 10, Active Comparator 3, Active Comparator 4
GlaxoSmithKline
Influenza, Human
11/24
06/25
NCT05469802: A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

Withdrawn
2
78
US
Purified Inactivated Zika Virus Vaccine (PIZV), TAK-426, Placebo
Takeda
Healthy Volunteers
07/24
07/24
NCT06560151: BARDA BP-I-23-001 H5 Influenza

Active, not recruiting
2
1380
US
3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A
Biomedical Advanced Research and Development Authority, Rho Federal Systems Division, Inc., ICON plc
Influenza
05/25
12/25
NCT06074562: A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Recruiting
2
410
Europe, Japan, US, RoW
LY3556050, Placebo
Eli Lilly and Company
Diabetic Peripheral Neuropathy
07/25
07/25
NCT05975840: Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults

Completed
1/2
518
US
FLU Q-PAN H5N8 Formulation 1, AS03B, AS03A, FLU Q-PAN H5N8 Formulation 2
GlaxoSmithKline
Influenza, Human
12/23
05/24
NCT06382311: A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults

Recruiting
1/2
1080
US
Flu Pandemic mRNA_Dose level 1, Flu Pandemic mRNA_Dose level 2, Flu Pandemic mRNA_ Dose level 3., Flu Pandemic mRNA_ Dose level 4, Flu Pandemic mRNA_Dose level 5, Flu Pandemic mRNA_Dose level 6, Flu Pandemic mRNA_Dose level 7, Placebo
GlaxoSmithKline
Influenza, Human
08/24
05/25
NCT05823974: A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

Active, not recruiting
1/2
1256
Europe, Canada, US, RoW
Flu mRNA, GSK4382276A, Control 1, Control 2
GlaxoSmithKline, CureVac
Influenza, Human
07/24
08/24
NCT06179290: Changes in Biomarker of Exposure in Adults Who Smoke Cigarettes Switching From Cigarettes to Heated Tobacco Products

Active, not recruiting
N/A
300
US
Ploom HTP Menthol HTS; MX3 (681), Ploom HTP Tobacco HTS; R8 (120), Smoking Abstinence (menthol), Smoking Abstinence (non-menthol)
Altria Client Services LLC, Celerion
Tobacco Use
05/24
03/25
NCT06356610: Pharmacokinetic and Subjective Effects of Heated Tobacco Products

Active, not recruiting
N/A
60
US
Test Product A, Ploom® 3.1 HTP - Menthol HTS; MX3 (681), Test Product B, Ploom® 3.1 HTP - Menthol HTS; MX5 (706), Test Product C, Ploom® 3.1 HTP - Tobacco HTS; R8 (120), Test Product D, Ploom® 3.1 HTP - Tobacco HTS; RX4 (953), Reference Product E, Nicorette® 4 mg Mint Nicotine Gum, Reference Product F, Combustible Cigarette (menthol or nonmenthol), participant's usual brand
Altria Client Services LLC, Celerion
Tobacco Use
04/24
06/25
NCT06777784: Modern Nicotine Oral Product Abuse Liability

Not yet recruiting
N/A
40
US
Product A, Product B, Product C, Product D, Product E, Product F, Product G, Product N
RAI Services Company
Smoking, Tobacco Use
06/25
02/26
SwissNeoNet, NCT04239508: Swiss Neonatal Network & Follow-up Group

Recruiting
N/A
1000
Europe
Swiss Neonatal Network, Department of Neonatology, Children's Clinic, Cantonal Hospital Aarau, Switzerland, Department of Neuropaediatrics, Children's Clinic, Cantonal Hospital Aarau, Switzerland, Department of Neonatology, University of Basel Children's Hospital (UKBB), Switzerland, Department of Neuropaediatrics and Developmental Medicine, University of Basel Children's Hospital (UKBB), Switzerland, Department of Pediatrics, San Giovanni Hospital Bellinzona, Switzerland, Department of Neonatology, University Hospital Berne, Switzerland, Department of Neuropaediatrics, University Hospital Berne, Switzerland, Development and Pediatric Neurorehabilitation Center, Biel, Switzerland, Department of Neonatology, Children's Hospital Chur, Switzerland, Department of Neuropaediatrics, Children's Hospital Chur, Switzerland, Department of Neuropediatrics, Cantonal Hospital Fribourg, Switzerland, Department of Neonatology, University Hospital Lausanne (CHUV), Switzerland, Department of Child Development, University Hospital Lausanne (CHUV), Switzerland, Department of Neonatology, University Hospital Geneva (HUG), Switzerland, Division of Development and Growth, University Hospital Geneva (HUG), Switzerland, Neonatal and Paediatric Intensive Care Unit, Children's Hospital of Lucerne, Switzerland, Department of Neuropaediatrics, Children's Hospital of Lucerne, Switzerland, Department of Pediatrics, Cantonal Hospital Muensterlingen, Switzerland, Department of Pediatrics, Cantonal Hospital Neuchatel, Switzerland, Department of Neonatology, Cantonal Hospital St. Gallen, Switzerland, Neonatal and Paediatric Intensive Care Unit, Children's Hospital St. Gallen, Switzerland, Department of Child Development, Children's Hospital St. Gallen, Switzerland, Department of Neonatology, Cantonal Hospital Winterthur, Switzerland, Social Pediatrics Center, Cantonal Hospital Winterthur, Switzerland, University Hospital, Zürich, University Children's Hospital, Zurich
Very Low Birth Weight Infant, Very Preterm Maturity of Infant, Asphyxia Neonatorum
12/50
12/50
Lee, Elaine Y
ATHENA, NCT05678738: Acquiring and Targeting Heat Exposures Necessary for Action

Recruiting
N/A
60
US
Antioxidant Berry Supplementation, Acute and Chronic Exercise-Heat Stress, Placebo (non-juice) Supplementation
University of Connecticut, United States Department of Defense
Heat Intolerance, Heat Stress, Fatigue; Heat
10/24
10/24
Weinstock, George
No trials found

Download Options